Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Johannes Weller(University Hospital Bonn), Niklas Schäfer(University Hospital Bonn), Stefanie Brehmer(Montreal Neurological Institute and Hospital), Roland Goldbrunner(University of Cologne), Clemens Seidel(Leipzig University), Christina Schaub(University of Bonn), Matthias Simon(University of Bonn), Sied Kebir(University of Bonn), Rolf Fimmers(University of Bonn), Peter Hau(University Hospital Regensburg), Oliver Bähr(Antea Group (France)), Lars Bullinger(Stanford University), Oliver Grauer(University Hospital Münster), Norbert Galldiks(Forschungszentrum Jülich), Theophilos Tzaridis(Sanford Burnham Prebys Medical Discovery Institute), Uwe Schlegel(Defence Research and Development Organisation), Walter Stummer(University of Münster), Ulrich Herrlinger(University of Tübingen), Christoph Coch(University of Bonn), Joachim P. Steinbach(Goethe University Frankfurt), Ghazaleh Tabatabai(Goethe University Frankfurt), Frederic Mack(University of Bonn), Martin Glas(Essen University Hospital), Martin Uhl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Dietmar Krex
Cited by 47
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
|The Lancet Oncology|2006|3.4k
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
|Neurosurgery|2008|1k
Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
|New England Journal of Medicine|2004|997